Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Effects of SHR4640 on Repaglinide and Midazolam and QT Interval
NCT06196580Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzinurad in gout and hyperuricemia (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 2 more. Started Jan 2024; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06196580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196580.